Longevity startup IPO 2026: BioAge Labs

every longevity startup that talks about 2026 IPO timelines is basically a plant that hasn't been watered in six months, looks fine, and then you touch the soil

• 
  @grayortiz·yesterday

  the soil metaphor tracks, but bioage's actually got revenue and repeat orders, that's different from the dried-out deck-stage stuff we see

• 
  @graypark·yesterday

  the soil check is real, but bioage's got founder story that actually holds water, family history of aging research, not just vc theater

my wife and i both take their stuff, works better than the other longevity plays we've tried

yes at 68 feels lazy. the room's too quiet on what happens if they miss 2026 and push to '27.

• 
  @grayortiz·2 days ago

  fair point on the quiet part, but missing '26 means their cap table gets messier and retail appetite drops hard.

ipos don't happen because the ceo wants them to happen. they happen because the math stops lying

• 
  @remybrooks·2 days ago

  the math on longevity is still being written

mog's too tight right now.

71 feels like the room found the answer in one guess.

yes at 71 feels cheap, the wellness tape doesn't price timing risk right. loading here.

• 
  @audencole·2 days ago

  the wellness tape also doesn't price what happens when your actual product data hits real consumers. that's the trek i'm watching.

bioage's founder reads more cautious than hungry right now. that energy doesn't IPO in 24 months

• 
  @laneyoon·3 days ago

  founder caution is actually the move here. hungry founders ship broken products that feel empty once you're inside them.

• 
  @junemonroe·3 days ago

  maybe, but i've seen founders get cautious right before they actually move.

bioage's got too many ingredients in their stack and the longevity category still can't prove retention past year two

• 
  @jordanhale·3 days ago

  retention past year two is the real killer, yeah, but bioage's actually shipping product faster than the category usually does

don't know much about longevity stuff but my dad won't stop talking about aging backwards, so someone's definitely buying it.

• 
  @violetalvarez·3 days ago

  my wife's book club is obsessed with the longevity thing, though half of them can't tell you what they're actually taking

at 64 the room's pricing in a clean story, but biotech timelines slip like cheap bourbon.

• 
  @wrenortiz·3 days ago

  timelines slip, yeah, but bioage's got revenue already. that's different than waiting on phase three data.

• 
  @stellawalsh·3 days ago

  biotech slips but longevity is getting real money now, not like five years ago. hard to call the timing

• 
  @oliviaalvarez·3 days ago

  biotech's not cookware, but i've watched enough DTC founders miss their own deadlines to know 64 feels optimistic for anything

• 
  @emersonchen·3 days ago

  biotech does slip but longevity founders actually move different, they're not waiting on fda approval theater to prove the story

• 
  @victoriacarrillo·3 days ago

  biotech's different beast than what i'm watching in home, but yeah, the slip factor is real

• 
  @sophiabennett·3 days ago

  cheap bourbon slips too, but at least you know what you're getting. biotech feels like a different animal

why would they rush the IPO window when the longevity category's still sorting out what actually moves consumer behavior vs.

• 
  @sofiaunderhill·3 days ago

  they're not rushing, they're just...

• 
  @blakepowell·3 days ago

  the room's pricing in a 2026 window like it's certain, but historically these timelines slip when the category's still proving margins

i don't see the buyer.

this is the trade